英国CD19 CAR-T治疗大B细胞淋巴瘤的国家级服务真实世界经验
该研究纳入2018年12月至2020年11月英国所有CAR-T中心经国家CAR-T临床专家组批准接受CAR-T治疗的连续复发/难治性大B细胞淋巴瘤患者,432例中404例获批(292例阿基仑赛,112例替沙仑赛),300例(74%)实际输注。输注患者6个月完全缓解率为38.3%,阿基仑赛与替沙仑赛的总缓解率分别为77%(完全缓解52%)和57%(完全缓解44%),12个月无进展生存率分别为41.8%和27.4%。
要点
- 404/432例获批患者中300例(74%)接受CAR-T输注。
- 输注患者6个月完全缓解率为38.3%(110/300)。
- 阿基仑赛总缓解率77%(完全缓解52%),替沙仑赛57%(完全缓解44%)。
核心结论
- 该前瞻性真实世界队列确认CD19 CAR-T在接受与关键试验类似治疗的患者中具有长期疗效,但早期CAR-T失败具有重要意义。
研究设计与样本
- 前瞻性真实世界队列,纳入2018年12月至2020年11月英国所有CAR-T中心经国家CAR-T临床专家组批准接受CAR-T治疗的连续复发/难治性大B细胞淋巴瘤患者。
- 432例中404例获批(292例阿基仑赛,112例替沙仑赛),300例(74%)接受细胞输注。
主要发现
- 输注患者6个月完全缓解率为38.3%(110/300)。
- 阿基仑赛总缓解率为77%(完全缓解52%),替沙仑赛总缓解率为57%(完全缓解44%)。
- 12个月无进展生存率:阿基仑赛41.8%,替沙仑赛27.4%。
- 意向治疗人群中位总生存期为10.5个月,输注患者为16.2个月。
- ≥3级细胞因子释放综合征和神经毒性发生率:阿基仑赛分别为7.6%和19.6%,替沙仑赛分别为7.9%和3.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national cohort of patients intended to be treated with CAR-T in the UK. Consecutive patients with r/r LBCL approved for CAR-T by the National CAR-T Clinical Panel between December 2018 and November 2020 across all UK CAR-T centres were included. 404/432 patients were approved [292 axicabtagene ciloleucel (axi-cel), 112 tisagenlecleucel (tisa-cel)], 300 (74%) received the cells. 110/300 (38.3%) patients achieved complete remission (CR) at 6 months (m). The overall response rate was 77% (52% CR) for axi-cel, 57% (44% CR) for tisa-cel. The 12-month progression-free survival was 41.8% (axi-cel) and 27.4% (tisa-cel). Median overall survival for the intention-to-treat population was 10.5 m, 16.2 m for infused patients. The incidence of grade ≥3 cytokine release syndrome and neurotoxicity were 7.6%/19.6% for axi-cel and 7.9%/3.9% for tisa-cel. This prospective RW population of CAR-T eligible patients offers important insights into the clinical benefit of CD19 CAR-T in LBCL in daily practice. Our results confirm long-term efficacy in patients receiving treatment similar to the pivotal trials, but highlight the significance of early CAR-T failure.
引用
- Kuhnl A, Roddie C, Kirkwood AA, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol. 2022. PMID: 35485402. doi:10.1111/bjh.18209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。